SEC Filing Summary: BioSig Technologies, Inc. (BSGM)
Business Context and Reporting Period
This Form 8-K was filed by BioSig Technologies, Inc. on September 4, 2020, reporting events occurring on September 2, 2020. The Company, incorporated in Delaware and trading on the NASDAQ Capital Market under the symbol BSGM, operates in the medical technology sector. The filing serves as a Regulation FD disclosure regarding an upcoming investor call.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event notification and does not contain financial statements or performance data.
Material Changes
No material financial changes versus prior periods are reported in this document. The primary event is the announcement of a conference call scheduled for September 15, 2020, to discuss results from the first randomized, blinded signal sample analysis in the PURE EP 2.0 Clinical Study.
Outlook, Risks, and Management Commentary
- Upcoming Event: The Company will host a call on September 15, 2020, at 11:00 AM Eastern Time to present clinical study results.
- Forward-Looking Statements: The Company explicitly states it undertakes no obligation to update, supplement, or amend the materials attached to this filing.
- Legal Disclaimer: Information in Item 7.01 is not deemed "filed" under Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the date and time of the conference call (September 15, 2020, 11:00 AM ET).
- Review the attached press release (Exhibit 99.1) for details on the PURE EP 2.0 Clinical Study.
- Confirm the trading symbol (BSGM) and exchange (NASDAQ Capital Market) for accurate market data tracking.
- Note that this filing contains no audited financial data; refer to the most recent 10-Q or 10-K for financial metrics.